文献速递瓣膜病与结构性心脏病

外科生物瓣衰败后经导管主动脉瓣植入:PARTNER 2 Valve-in-Valve注册研究

Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses: PARTNER 2 Valve-in-Valve Registry.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

PARTNER 2 VIV注册研究前瞻性纳入365例外科主动脉生物瓣衰败且再手术高危的患者,行经导管瓣中瓣主动脉瓣置换。30天全因死亡2.7%、卒中2.7%,1年全因死亡12.4%;从初始注册组到继续准入组,30天死亡率(8.2% vs 0.7%)和1年死亡率(19.7% vs 9.8%)均下降。

要点

  • 高危外科生物瓣衰败患者行瓣中瓣TAVR,30天全因死亡2.7%、卒中2.7%。
  • 从初始注册组到继续准入组,30天死亡率8.2% vs 0.7%,1年死亡率19.7% vs 9.8%,均下降。
  • 1年平均跨瓣压差17.6 mmHg,有效瓣口面积1.16 cm2,>轻度瓣周漏1.9%。

核心结论

  • 在高危患者中,针对生物瓣主动脉瓣衰败的TAVR与相对较低的死亡率和并发症率相关,并改善血流动力学及1年功能和生活质量结局。

研究设计与样本

  • 前瞻性纳入多中心PARTNER 2 VIV试验和继续准入注册研究,共365例外科主动脉生物瓣症状性衰败且再手术高危(≥50%主要并发症或死亡风险)患者。
  • 平均年龄78.9 ± 10.2岁,平均STS评分9.1 ± 4.7%。
  • 共365例患者中,初始注册96例,继续准入269例。

主要发现

  • 30天全因死亡2.7%,卒中2.7%,主要血管并发症4.1%,中转外科手术0.6%,冠状动脉闭塞0.8%,新置入起搏器1.9%。
  • 1年全因死亡12.4%。
  • 从初始注册组到继续准入组,30天死亡率8.2% vs 0.7%(p = 0.0001),1年死亡率19.7% vs 9.8%(p = 0.006),均下降。
  • 1年平均跨瓣压差17.6 mmHg,有效瓣口面积1.16 cm2,>轻度瓣周漏1.9%。
  • 左室射血分数从50.6%增至54.2%,质量指数从135.7降至117.6 g/m2;二尖瓣中重度反流从34.9%降至12.7%,三尖瓣从31.8%降至21.2%(均p < 0.0001)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early experience with transcatheter aortic valve replacement (TAVR) within failed bioprosthetic surgical aortic valves has shown that valve-in-valve (VIV) TAVR is a feasible therapeutic option with acceptable acute procedural results. OBJECTIVES: The authors examined 30-day and 1-year outcomes in a large cohort of high-risk patients undergoing VIV TAVR. METHODS: Patients with symptomatic degeneration of surgical aortic bioprostheses at high risk (≥50% major morbidity or mortality) for reoperative surgery were prospectively enrolled in the multicenter PARTNER (Placement of Aortic Transcatheter Valves) 2 VIV trial and continued access registries. RESULTS: Valve-in-valve procedures were performed in 365 patients (96 initial registry, 269 continued access patients). Mean age was 78.9 ± 10.2 years, and mean Society of Thoracic Surgeons score was 9.1 ± 4.7%. At 30 days, all-cause mortality was 2.7%, stroke was 2.7%, major vascular complication was 4.1%, conversion to surgery was 0.6%, coronary occlusion was 0.8%, and new pacemaker insertion was 1.9%. One-year all-cause mortality was 12.4%. Mortality fell from the initial registry to the subsequent continued access registry, both at 30 days (8.2% vs. 0.7%, respectively; p = 0.0001) and at 1 year (19.7% vs. 9.8%, respectively; p = 0.006). At 1 year, mean gradient was 17.6 mm Hg, and effective orifice area was 1.16 cm2, with greater than mild paravalvular regurgitation of 1.9%. Left ventricular ejection fraction increased (50.6% to 54.2%), and mass index decreased (135.7 to 117.6 g/m2), with reductions in both mitral (34.9% vs. 12.7%) and tricuspid (31.8% vs. 21.2%) moderate or severe regurgitation (all p < 0.0001). Kansas City Cardiomyopathy Questionnaire score increased (mean: 43.1 to 77.0) and 6-min walk test distance results increased (mean: 163.6 to 252.3 m; both p < 0.0001). CONCLUSIONS: In high-risk patients, TAVR for bioprosthetic aortic valve failure is associated with relatively low mortality and complication rates, improved hemodynamics, and excellent functional and quality-of-life outcomes at 1 year. (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves [PARTNER II]; NCT01314313).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Webb JG, Mack MJ, White JM, et al. Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses: PARTNER 2 Valve-in-Valve Registry. J Am Coll Cardiol. 2017. PMID: 28473128. doi:10.1016/j.jacc.2017.02.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。